Bristol Myers drops cell therapy pacts with Immatics, Century as part of...
Bristol Myers Squibb is ending a pair of cell therapy collaborations with Immatics and nixing a separate agreement with Century Therapeutics for natural killer cell and T cell-based cancer treatments....
View ArticleNovo Nordisk to spend $1.2B for new rare disease drug factory in Denmark
Just days after winning FTC approval to take on three of Catalent’s facilities, Novo Nordisk said it is investing DKK 8.5 billion ($1.2 billion) to build a new factory in Denmark to ...
View ArticleBiohaven’s protein degrader cuts antibodies by 60%
Biohaven said the lowest dose of BHV-1300 cut the levels of the autoimmune antibody IgG by more than 60%, according to a new cut of data from an ongoing multiple ascending dose trial. This falls ...
View ArticlePureTech declares mid-stage trial win for pulmonary fibrosis drug
PureTech Health unveiled positive Phase 2b data on Monday for its idiopathic pulmonary fibrosis drug, which showed it can reduce lung function decline in patients. The drug hit the trial's primary ...
View ArticleCandid inks three T cell engager deals; PepGen trial put on hold
Plus, news about Foghorn Therapeutics, Incyte, BioNTech, Galderma, Basilea, Innovia, Pharming, bit.bio, Promise Bio, Outlook Therapeutics and Trevi Therapeutics: Candid Therapeutics’ trio of T cell...
View ArticleCheckpoint wins FDA approval of checkpoint inhibitor in advanced skin cancer,...
The FDA approved Checkpoint Therapeutics’ anti-PD-L1 antibody cosibelimab in a form of advanced skin cancer, the company announced Friday. The immune checkpoint drug will be marketed as Unloxcyt and...
View ArticleNeurocrine gets FDA approval in rare adrenal gland condition
A turbulent 2024 for Neurocrine is ending on a high note, after the biotech won FDA approval to treat congenital adrenal hyperplasia, a condition marked by adrenal gland dysfunction. The Friday
View ArticleHRSA pushes back against another 340B rebate model, this time from Sanofi
The US Health Resources and Services Administration on Friday warned Sanofi against implementing its planned rebate model for some of its outpatient drugs under the drug discount program for low income...
View ArticleWhat a Trump FTC means for biotech and pharma dealmaking
President-elect Donald Trump’s two picks for the Federal Trade Commission are likely to usher in more life sciences deals while maintaining the agency’s pressure on pharmaceutical intermediaries. A...
View ArticleViridian readies for Tepezza rivalry with new Phase 3 data in thyroid eye...
Viridian Therapeutics’ stock jumped Monday after the company unveiled another Phase 3 look at its potential competitor to Amgen's Tepezza in thyroid eye disease. Veligrotug met all its primary and...
View ArticleAstraZeneca denied full FDA approval of Andexxa after adcomm
AstraZeneca said the FDA declined to fully approve its anticoagulant reversal drug Andexxa, less than a month after an advisory committee meeting at which the agency and a group of outside advisors...
View ArticleFood as medicine could get boost from Trump presidency
The concept that doctors can improve patients’ health by prescribing certain foods, just as they do medicines, has been hovering on the fringes of the healthcare industry for decades. Recently, that...
View ArticleShinobi adds Borges as science chief, Katz as top medical officer
Shinobi Therapeutics, an off-the-shelf cell therapy developer, told Endpoints News it has hired its first chief scientific and medical officers as it also nabs two leaders in the cell therapy field for...
View ArticleMerck winds down TIGIT, LAG-3 programs meant to temper Keytruda erosion
After multiple clinical failures, it’s finally the end of the road for Merck’s TIGIT program. The company is dropping development of its anti-TIGIT candidate vibostolimab after two more Phase 3 studies...
View ArticleFDA rejects J&J’s subcutaneous Rybrevant over manufacturing issues
The FDA has issued a complete response letter to Johnson & Johnson for the subcutaneous version of its lung cancer drug Rybrevant after issues were found during a pre-approval inspection of a...
View ArticleTeva and Sanofi report Phase 2b data for duvakitug in IBD
Teva and Sanofi announced positive mid-stage results ahead of schedule for their irritable bowel disease candidate as they look to keep pace in an anti-TL1A race with Merck and Roche. The duo’s...
View ArticleEmployee lawsuit over J&J's own health costs may loosen PBMs' grip
Ann Lewandowski knows all about pharmacy benefit managers, or PBMs, the companies that shape the US drug market. Her job as a policy advocate at Johnson & Johnson was to tell patient and physician...
View ArticleUCB, Novartis say a Phase 2a Parkinson's study failed
UCB and Novartis ended development on the lead program in their partnership after reporting a Phase 2a failure in Parkinson’s disease. The companies said Monday that minzasolmin, a small molecule...
View ArticleChicago’s biotech scene is growing up. What’s fueling it?
CHICAGO — Over the years, a handful of cities have tried catching up to the flourishing biotech hubs in Boston or the San Francisco Bay Area. Chicago, the third-largest city in the US, is putting ...
View Article